Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.

Abstract: A process for melting metal parts and casting the melt in at least one mould and a corresponding combined melting and casting furnace plant are described. In the process, metal parts to be melted are brought into a crucible furnace, and a molten metal is produced therein and made ready for casting. A riser tube integrated in a lid of the crucible furnace is heated in a position remote from the crucible furnace, and the lid with heated riser tube is brought into a position closing the crucible furnace, in which the riser tube projects into the molten metal. A mould is arranged on the lid in a casting position above the riser tube, and the molten metal is introduced into the mould from below by pressurising the melt in the crucible furnace. The combined melting and casting furnace plant is designed to carry out such a process.

Abstract: A process for melting metal parts and casting the melt in at least one mould and a corresponding combined melting and casting furnace plant are described. In the process, metal parts to be melted are brought into a crucible furnace, and a molten metal is produced therein and made ready for casting. A riser tube integrated in a lid of the crucible furnace is heated in a position remote from the crucible furnace, and the lid with heated riser tube is brought into a position closing the crucible furnace, in which the riser tube projects into the molten metal. A mould is arranged on the lid in a casting position above the riser tube, and the molten metal is introduced into the mould from below by pressurising the melt in the crucible furnace. The combined melting and casting furnace plant is designed to carry out such a process.

Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.

Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.

Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.

Abstract: A mould (1) for the manufacture of a casting (2) using moulding material (3). In order to achieve simple and cheap manufacture, the mould (1) is provided with an outer first mould carrier (4), an outer second mould carrier (5), a mould body (6) arranged between said mould carriers (4, 5) and an inner layer (12) of moulding material (3) applied to said mould carrier (6) at least in areas, to form the mould cavity.

Abstract: The invention relates to a mould (1) for the manufacture of a casting (2) using moulding material (3). In order to achieve simple and cheap manufacture, the mould (1) is provided with an outer first mould carrier (4), an outer second mould carrier (5), a mould body (6) arranged between said mould carriers (4, 5) and an inner layer (12) of moulding material (3) applied to said mould carrier (6) at least in areas, to form the mould cavity.